After the market close on Tuesday, the provider of health information services reported earnings of 60 cents per share, higher than analysts' forecasts for earnings of 57 cents per share.
Revenue of $192.1 million beat analysts' estimates for revenue of $189.93 million. Advertising and sponsorship revenue climbed by about 24.6% year-over-year during the quarter.
Additionally, traffic to the company's website rose by 6% to an average of 201 million unique users per month during the quarter.
Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rates this stock as a "buy" with a ratings score of B-. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow.
You can view the full analysis from the report here: WBMD